UB-612, a Multitope Universal Vaccine Eliciting a Balanced B and T Cell Immunity against SARS-CoV-2 Variants of Concern

Design of Extension Booster Trial, Objectives, and Oversight

Vaccine Product and Placebo

Like the same vaccine product used in the Phase-1 primary and booster and the Phase-2 primary trials, UB-612 vaccine used in the present phase-2 extension booster vaccination is a multitope vaccine designed to activate both humoral and cellular responses. For SARS-CoV-2 immunogens, UB-612 combines a CHO-expressed S1-RBD-sFc fusion protein (Wuhan strain) and a mixture of synthetic T helper (Th) and cytotoxic T lymphocyte (CTL) epitope peptides, which are selected from immunodominant M, S2 and N regions known to bind to human major histocompatibility complexes (MHC) I and II. The preparation of UB-612 vaccine product consists of compounding, filtration, mixing, and filling operations. Before addition of the subunit protein S1-RBD-sFc, the individual components of the vaccine are filtered through a 0.22 micron membrane filter, including the peptide solution (2 µg/mL), CpG1, a proprietary oligonucleotide (ODN), solution (2 µg/mL), 10X protein buffer containing 40 mM Histidine, 500 mM Arginine and 0.6% Tween 80, 20% sodium chloride stock solution. After sequentially addition of each component, the S1-RBD-sFc fusion protein and peptides are formulated with components described as above to form a protein-peptide complex and then is adsorbed to aluminum phosphate (Adju-Phos®) adjuvant. The last step would be addition of water for injection containing the 2-phenoxyethanol preservative solution to make final drug product at 200 µg/mL. The UB-612 vaccine product is stored at 2 to 8 °C. Placebo used in the Phase-2 trial was sterile 0.9% normal saline.

Trial Procedures and Safety

Scope of Immunogenicity Investigation

The primary immunogenicity endpoints were the geometric mean titers (GMT) of neutralizing antibodies against SARS-CoV-2 wild-type (WT, Wuhan strain), and the post-booster effects against Omicron and Delta variant were explored as well. For WT and Delta strains, viral-neutralizing antibody titers that neutralize 50% (VNT50) of live SARS-CoV-2 WT and Delta variant were measured by a cytopathic effect (CPE)-based assay using Vero-E6 (ATCC® CRL-1586) cells challenged with SARS-CoV-2-Taiwan-CDC#4 (Wuhan strain) and SARS-CoV-2-Taiwan-CDC#1144 (B.1.617.2; Delta variant). The replicating virus neutralization test conducted at Academia Sinica was fully validated using internal reference controls and results expressed as VNT₅₀. The WHO reference standard was also employed and results reported in international units (IU/mL). For WT and Omicron strains, 50% pseudovirus neutralization titers (pVNT₅₀) were measured by neutralization assay using HEK-293T-ACE2 cells challenged with SARS-CoV-2 pseudovirus variants expressed the spike protein of WT and Omicron BA.1variants. Assay methods are detailed below.

The secondary immunogenicity endpoints include anti-S1-RBD IgG antibody, inhibitory titers against S1-RBD:ACE2 interaction, and T-cell responses assayed by ELISpot and Intracellular Staining. The RBD IgG ELISA was fully validated using internal reference controls and results expressed in end-point titers. The WHO reference standard was also employed and results reported in Binding Antibody Units (BAU/mL) (70, Lancet 2021;397(10282):1347-1348.). A panel of 20 human convalescent serum samples from COVID-19 Taiwan hospitalized patients aged 20 to 55 years were also tested for comparison with those in the vaccinees. Human peripheral blood mononuclear cells (PBMCs) were used for monitoring T cell responses. All bioassay methods are detailed below.

Viral-neutralizing antibody titers against SARS-CoV-2 wild-type and variants by CPE based live virus neutralization assay

Neutralizing antibody titers were measured by CPE-based live virus neutralization assay using Vero-E6 cells challenged with wild type (SARS-CoV-2-Taiwan-CDC#4, Wuhan) and Delta variant (SARS-CoV-2-Taiwan-CDC#1144, B.1.617.2), which was conducted in a BSL-3 lab at Academia Sinica, Taiwan. Vero-E6 (ATCC® CRL-1586) cells were cultured in DMEM (Hyclone) supplemented with 10% fetal bovine serum (FBS, Gibco) and 1x Penicillin-Streptomycin solution (Thermo) in a humidified atmosphere with 5% CO₂ at 37°C. The 96-well microtiter plates are seeded with 1.2×10⁴ cells/100 μL/well. Plates are incubated at 37° C in a CO₂ incubator overnight. The next day tested sera were heated at 56 °C for 30 min to inactivate complement, and then diluted in DMEM (supplemented with 2% FBS and 1x Penicillin/Streptomycin). Serial 2-fold dilutions of sera were carried out for the dilutions. Fifty μL of diluted sera were mixed with an equal volume of virus (100 TCID50) and incubated at 37°C for 1 hr. After removing the overnight culture medium, 100 μL of the sera-virus mixtures were inoculated onto a confluent monolayer of Vero-E6 cells in 96-well plates in triplicate. After incubation for 4 days at 37 °C with 5% CO₂, the cells were fixed with 10% formaldehyde and stained with 0.5% crystal violet staining solution at room temperature for 20 min. Individual wells were scored for CPE as having a binary outcome of ‘infection” or ‘no infection’. Determination of SARS-CoV-2 virus specific neutralization titer was to measure the neutralizing antibody titer against SARS-CoV-2 virus based on the principle of VNT50 titer (≥50% reduction of virus-induced cytopathic effects). Virus neutralization titer of a serum was defined as the reciprocal of the highest serum dilution at which 50% reduction in cytopathic effects are observed and results are calculated by the method of Reed and Muench.

Neutralizing Antibody Titers against Omicron strain by pesudovirus luciferase assay

Neutralizing antibody titers were measured by neutralization assay using HEK-293T-ACE2 cells challenged with SARS-CoV-2 pseudovirus variants. The study was conducted in a BSL2 lab at RNAi core, Biomedical Translation Research Center (BioTReC), Academia Sinica. Human embryonic kidney (HEK-293T/17; ATCC® CRL-11268™) cells were obtained from the American Type Culture Collection (ATCC). Cells were cultured in DMEM (Gibco) supplemented with 10% fetal bovine serum (Hyclone) and 100 U/mL of Penicillin-Streptomycin solution (Gibco), and then incubated in a humidified atmosphere with 5% CO2 at 37 °C. HEK-293T-ACE2 cells were generated by transduction of VSV-G pseudotyped lentivirus carrying human ACE2 gene. To produce SARS-CoV-2 pseudoviruses, a plasmid expressing C-terminal truncated wild-type Wuhan-Hu-1 strain SARS-CoV-2 spike protein (pcDNA3.1-nCoV-SΔ18) was co-transfected into HEK-293T/17 cells with packaging and reporter plasmids (pCMVΔ8.91, and pLAS2w.FLuc.Ppuro, respectively) (BioTReC, Academia Sinica), using TransIT-LT1 transfection reagent (Mirus Bio). Site-directed mutagenesis was used to generate the Omicron BA.1variants by changing nucleotides from Wuhan-Hu-1 reference strain. For BA.1 variant, the mutations of spike protein are A67V, Δ69-70, T95I, G142D/Δ143-145, Δ211/L212I, ins214EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, L981F. Indicated plasmids were delivered into HEK-293T/17 cells by using TransITR-LT1 transfection reagent (Mirus Bio) to produce different SARS-CoV-2 pseudoviruses. At 72 hours post-transfection, cell debris were removed by centrifugation at 4,000 xg for 10 minutes, and supernatants were collected, filtered (0.45 μm, Pall Corporation) and frozen at −80 °C until use. HEK-293-hACE2 cells (1×10⁴ cells/well) were seeded in 96-well white isoplates and incubated for overnight. Tested sera were heated at 56°C for 30 min to inactivate complement, and diluted in medium (DMEM supplemented with 1% FBS and 100 U/ml Penicillin/Streptomycin), and then 2-fold serial dilutions were carried out for a total of 8 dilutions. The 25 μL diluted sera were mixed with an equal volume of pseudovirus (1,000 TU) and incubated at 37 °C for 1 hr before adding to the plates with cells. After 1-hr incubation, the 50 μL mixture added to the plate with cells containing with 50 μL of DMEM culture medium per well at the indicated dilution factors. On the following 16 hours incubation, the culture medium was replaced with 50 μL of fresh medium (DMEM supplemented with 10% FBS and 100 U/ml Penicillin/Streptomycin). Cells were lysed at 72 hours post-infection and relative light units (RLU) was measured by using Bright-GloTM Luciferase Assay System (Promega). The luciferase activity was detected by Tecan i-control (Infinite 500). The percentage of inhibition was calculated as the ratio of RLU reduction in the presence of diluted serum to the RLU value of virus only control and the calculation formula was shown below: (RLU ^Control - RLU ^Serum) / RLU ^Control. The 50% protective titer (NT50 titer) was determined by Reed and Muench method.

Inhibition of RBDWT binding to ACE2 by ELISA

The 96-well ELISA plates were coated with 2 µg/mL ACE2-ECD-Fc antigen (100 μL/well in coating buffer, 0.1M sodium carbonate, pH 9.6) and incubated overnight (16 to 18 hr) at 4 °C. Plates were washed 6 times with Wash Buffer (25-fold solution of phosphate buffered saline, pH 7.0-7.4 with 0.05% Tween 20, 250 μL/well/wash) using an Automatic Microplate Washer. Extra binding sites were blocked by 200 μL/well of blocking solution (5 N HCl, Sucrose, Triton X-100, Casein, and Trizma Base). Five-fold dilutions of immune serum or a positive control (diluted in a buffered salt solution containing carrier proteins and preservatives) were mixed with a 1:100 dilution of RBDWT-HRP conjugate (horseradish peroxidase-conjugated recombinant protein S1-RBD-His), incubated for 30±2 min at 25±2 °C, washed and TMB substrate (3,3’,5,5’-tetramethylbenzidine diluted in citrate buffer containing hydrogen peroxide) is added. Reaction is stopped by stop solution (diluted sulfuric acid, H₂SO_4, solution, 1.0 M) and the absorbance of each well is read at 450nm within 10 min using the Microplate reader (VersaMax). Calibration standards for quantitation ranged from 0.16 to 2.5 μg/mL. Samples with titer value below 0.16 μg/mL were defined as being half of the detection limit. Samples with titer exceed 2.5 μg/mL were further diluted for reanalysis.

Anti-S1-RBD_WT binding IgG antibody by ELISA

The 96-well ELISA plates were coated with 2 µg/mL recombinant S1-RBD_WT-His protein antigen (100 µL/well in coating buffer, 0.1 M sodium carbonate, pH 9.6) and incubated overnight (16 to 18 hr) at room temperature. One hundred μL/well of serially diluted serum samples (diluted from 1:20, 1:1,000, 1:10,000 and 1:100,000, total 4 dilutions) in 2 replicates were added and plates are incubated at 37 °C for 1 hr. The plates were washed six times with 250 μL Wash Buffer (PBS-0.05% Tween 20, pH 7.4). Bound antibodies were detected with HRP-rProtein A/G at 37 °C for 30 min, followed by six washes. Finally, 100 μL/well of TMB (3,3’,5,5’-tetramethylbenzidine) prepared in Substrate Working Solution (citrate buffer containing hydrogen peroxide) was added and incubated at 37 °C for 15 min in the dark, and the reaction stopped by adding 100 μL/well of H₂SO_4, 1.0 M. Sample color developed was measured on ELISA plate reader (Molecular Device, VersaMax). UBI® EIA Titer Calculation Program was used to calculate the relative titer. The anti-S1-RBD antibody level is expressed as Log₁₀ of an end point dilution for a test sample (SoftMax Pro 6.5, Quadratic fitting curve, Cut-off value 0.248).

T cell responses by ELISPOT

Human peripheral blood mononuclear cells (PBMCs) were used in the detection of the T cell response. For the booster-series third-dose series extension study, ELISpot assays were performed using the human IFN-γ/IL-4 FluoroSpot^PLUS kit (MABTECH). Aliquots of 250,000 PBMCs were plated into each well and stimulated, respectively, with 10 μg/mL (each stimulator) of RBD-_WT+Th/CTL, Th/CTL, or Th/CTL pool without UBITh1a (CoV2 peptides), and cultured in culture medium alone as negative controls for each plate for 24 hours at 37 °C with 5% CO2. The analysis was conducted according to the manufacturer’s instructions. Spot-forming units (SFU) per million cells was calculated by subtracting the negative control wells.

Intracellular Cytokine Staining (ICS)

Intracellular cytokine staining and flow cytometry was used to evaluate CD4⁺ and CD8⁺ T cell responses. PBMCs were stimulated, respectively, with S1-RBD-His recombinant protein plus with Th/CTL peptide pool, Th/CTL peptide pool only, CoV2 peptides, PMA + Inonmycin (as positive controls), or cultured in culture medium alone as negative controls for 6 hours at 37°C with 5% CO₂. Following stimulation, cells were washed and stained with viability dye for 20 minutes at room temperature, followed by surface stain for 20 minutes at room temperature, cell fixation and permeabilization with the BD cytofix/cytoperm kit (Catalog # 554714) for 20 minutes at room temperature, and then intracellular stain for 20 minutes at room temperature. Intracellular cytokine staining of IFN-γ, IL-2 and IL-4 was used to evaluate CD4⁺ T cell response. Intracellular cytokine staining of IFN-γ, IL-2, CD107a and Granzyme B was used to evaluate CD8⁺ T cell responses. Upon completion of staining, cells were analyzed in a FACSCanto II flow cytometry (BD Biosciences) using BD FACSDiva software.

Statistics

For the Phase-2 extension booster vaccination study, the immunogenicity results for Geometric Mean Titer (GMT) are presented with the 95% confidence intervals. Statistical analyses were performed using SAS® Version 9.4 (SAS Institute, Cary, NC, USA) or Wilcoxon sign rank test. Spearman correlation was used to evaluate the monotonic relationship between non-normally distributed data sets. For the Phase-2 primary 2-dose series, the sample size of the trial design meets the minimum safety requirement of 3000 study participants in the vaccine group with healthy adults, as recommended by the US FDA and WHO.

US Food and Drug Administration, Emergency use authorization for vaccines to prevent COVID-19: Guidance for industry, https://downloads.regulations.gov/FDA-2020-D-1137-0019/attachment_1.pdf;

WHO Guidelines on clinical evaluation of vaccines: regulatory expectations, https://cdn.who.int/media/docs/default-source/prequal/vaccines/who-trs-1004-web-annex-9.pdf?sfvrsn=9c8f4704_2&download=true.

Phase-2 Booster Trial Population, Reactogenicity and Safety

Durable T Cells Responses Induced by Th/CTL Epitope Peptides

ELISpot

Vaccinees’ peripheral blood mononuclear cells (PBMCs) were collected for evaluation of Interferon-γ⁺ (IFN-γ⁺)-ELISpot. On Day 57 (28 days post-2^nd dose), IFN-γ SFU (Spot Forming Unit)/10⁶ cells under stimulation with RBD+Th/CTL increased from the baseline 1.0 to a high 374 SFU (Figure 2A), which maintained strong at 261 (70%) at pre-boosting (6-8 months post-2^nd dose), then rose to 444 SFU 14 days post-booster (Figure 2D). Similar IFN-γ profiles were observed for that stimulated with Th/CTL alone, which increased from the baseline 1.3 to a high 322 SFU on Day 57 (Figure 2A), maintained at 182 SFU (∼57%) at pre-boosting and remained strong at 317 SFU 14 days post-booster (Figure 2D). Apparently, T cell responses persisted robust (60-70% of the high peak at Day 57) long over 6-8 months.

• Download figure
• Open in new tab

Figure 2. UB-612 induced T cell responses measured by ELISpot and ICS analyses

T-cell responses to stimulation by epitope peptides (Th/CTL+RBD or Th/CTL alone) were analysed with PBMCs collected from 83 vaccinees from Immunogenicity group (n = 83) on Days 57 (28 days after 2^nd booster); and from 32 vaccinees from the Immunogenicity (n = 18) or Safety groups (n = 14) who joined the Phase-2 extension booster study to evaluate the T-cell responses in PBMCs on Days 197 to 242 (pre-boosting days) and Days 211 to 256 (14 days post-booster third dose). T-cell responses were measured by (A, D) IFN-γ and (B, E) IL-4 ELISpot at 10-ug/mL per stimulator. Spot-forming units (SFU) per 1×10⁶ PBMCs producing IFN-γ and IL-4 after stimulation with the RBD+Th/CTL peptide pool or the Th/CTL peptide pool are expressed. The PBMC samples stimulated with Th/CTL+RBD were also evaluated for T cell responses by Intracellular Staining (ICS) (C, F), by which the frequency of CD8⁺ T cells producing the measured cytokines (CD107a and Granzyme B) in response to the stimulation of RBD+Th/CTL peptide poolare shown. (G) Summary of mean and 95% CI are presented for plots as shown in Figures (A) to (F). Horizontal bars indicate mean with 95% CI.

These results indicate that UB-612 can induce a strong, durable IFN-γ⁺ T cell immunity in the primary series and prompt a high level of memory recall upon boosting, and that the presence of Th/CTL peptides is essential and principally responsible for the bulk of the T cell responses, while S1-RBD plays only a minor role. Together with the insignificant low levels of the IL-4⁺ ELISpot responses (Figures 2B and 2E), UB-612 vaccination at both primary series and homologous-boosting could induce pronounced Th1-predominant immunity.

Cross-reactive Neutralizing Antibodies against SARS-CoV-2 Omicron and Delta Variants

Anti-Omicron assay with pseudovirus

Based on pseudovirus neutralization assay and observed across all groups aged 18-85 years (n = 41), the UB-612 booster elicited a high geometric mean 50% neutralizing titer (pVNT₅₀) at 6,245 against wild-type Wuhan strain (WT) versus Omicron variant at 1,196, representing a 5.2-fold reduction (Figure 3A). There was no significant age-dependent booster-induced neutralization effect between young adults (18-65 years) and the elderly (65-85 years) with respect to either anti-WT or anti-Omicron pVNT₅₀ level (Figure 3B). Both age groups showed a 5.0- to 6.0-fold reduction for anti-Omicron relative to anti-WT, yet the pVNT₅₀ of 1,196 still represents a potent viral-neutralizing strength.

• Download figure
• Open in new tab

Figure 3. UB-612 booster induced potent neutralization effects against both Omicron and Delta variants

A total of 41 serum samples (n = 27 for 18-65 years; n = 14 for 65-85 years) from 14 days post-booster were subjected to a pseudovirus-luciferase neutralization assay for Omicron and a live virus CPE neutralization assay for Delta variant. The viral-neutralizing antibody geometric mean titers (GMT, 95% CI) that inhibit 50% of SARS-CoV-2 wild-type Wuhan strain (WT), Omicron and Delta were measured. Statistical analysis was performed by the Student’s t-test (ns, p>0.05; ****, p<0.0001). (A) The pVNT₅₀ titers 14 days post-booster reached at 6245 against SARS-CoV-2 WT, and at 1196 against Omicron. The 5.2-fold reduction stands for 19% preservation of neutralization titers relative the Wuhan wild type. (B) The pVNT₅₀ titers are presented by two age groups. (C) The VNT₅₀ titers 14 days post-booster reached at 1711 against live WT, and at 1282 against Delta. The 1.3-fold reduction stands for 75% preservation of neutralization titer relative to the WT. (D) The VNT₅₀ titers are presented by two age groups. (E) Summary of geometric mean titers (GMT) and 95% CI for plots shown in Figures (A) to (D).

Functional correlations between ACE2:RBD_WT binding inhibition and viral neutralization

Potent and durable viral-neutralization and ACE2:RBD_WT binding inhibition

In the Phase-2 extension booster Immunogenicity group, the immune sera from 87 participants available on Day 1 (pre-dose), Day 57 (28 days post-2^nd dose), Day 220 (pre-boosting, 6 to 8 months post-2^nd dose), and Day 234 (14 days post-booster) were assayed for neutralization against live WT strain, which showed a high post-booster VNT₅₀ titer of 738 (Figure 4A), a 17- fold increase over the pre-boosting (titer 44) and a 7-fold increase over the levels of both Day 57 (titer 104) and the human convalescent sera, HCS (titer 102).

• Download figure
• Open in new tab

Figure 4. Functional correlations between ACE2:RBD_WT binding inhibition and viral-neutralization

Of 871 participants enrolled in the Phase-2 primary 2-dose series and grouped for Immunogenicity investigation, serum samples from 87 participants who had received a booster 3^rd-dose of 100 μg UB-612 were collected at Day 1 (pre-dose 1), Day 57 (28 days post-dose 2), Day 220 (pre-booster between Days 197 to 242,), Day 234 (14 days post-booster between Days 211 to Day 256). HCS from 20 SARS-CoV-2 infected individuals were also included for comparative testing by two functional assays: (A) viral-neutralizing titer (VNT₅₀) against live wild-type Wuhan strain (WT) by CPE method; and (B) the antibody concentration calibrated with an internal standard for ACE2:RBD_WT binding inhibition by ELISA. The correlations are explored between the two function assays, i.e., ACE2:RBD_WT binding inhibition ELISA and the viral-neutralizing titers against the live virus (VNT₅₀ for original wild-type and Delta strains) or the psuedovirus (pVNT₅₀ for Omicron strain). The RBD_WT stands for the RBD binding protein domain bearing amino acid sequence of the original SARS-CoV-2 wild-type (WT) Wuhan strain. The correlations were explored for (C) ACE2:RBD_WT inhibition vs. anti-WT VNT₅₀, (D) ACE2:RBD_WT inhibition vs. anti-Delta VNT₅₀, and (E) ACE2:RBD_WT inhibition vs. anti-Omicron pVNT₅₀. The correlation coefficients were evaluated by Spearman r with 95% CI. Statistical analysis was performed with the Student’s t-test (ns, p>0.05; ***, p<0.001; ****, p<0.0001). (F) Summary of geometric mean titer (GMT) and 95% CI are presented for plots as shown in Figures (A) and (B).

A striking post-booster functional antibody-mediated inhibition of ACE2:RBD_WT binding on ELISA was notable at a high titer (expressed in standard-calibrated antibody concentration) of 198 μg/mL (Figure 4B), a ∼57-fold increase over both the pre-boosting titer of 3.5 μg/mL and the Day 57 titer of 3.5 μg/mL, and a profound 140-fold over the HCS titer of 1.4 μg/mL. As the ELISA methodology measures neutralizing (inhibitory) antibodies against RBD_WT binding to ACE2 receptor, the low HCS titer suggests that the majority of antibodies in HCS appears to bind more to the allosteric sites (N- or C-terminal domain of the S1) than to the orthosteric (RBD) sites.

Of note, UB-612 induces a durable neutralizing antibody titer level, observed between Day 57 (post-2^nd dose) vs. Day 220 (pre-boosting), a 42% retainment for VNT₅₀ (titer, 104 vs. 44) against live WT virus (Figure 4A) and a 88% retainment for ACE2:RBD_WT (μg/mL, 4.0 vs. 3.5) binding inhibition (Figure 4B).

The neutralization of ACE2:RBD_WT binding on ELISA correlates well with both anti-WT (Figure 4C) and anti-Delta VNT₅₀ (Figure 4D) findings, both showed a similar high correlative Spearman r = 0.795 and 0.828, respectively. A lesser but significant correlation exists for ACE2:RBD_WT binding inhibition and anti-Omicron pVNT₅₀, with a Spearman r = 0.565 (Figure 4E).

Limitation

This study has four limitations. First, UB-612 has not yet been widely deployed geographically. Second, in-depth biomarker analysis beyond those described in this report was not conducted due to insufficient volume of blood and samples retained. Third, we used Th/CTL peptide pool for an overall in vitro assessment of immune enhancement upon booster without delineation as to which peptide contributes most to mounting T-cell immunity in each of the vaccinees, though pooling may produce synergistic effect. Fourth, the post-booster functional analyses were carried out for a short period of time, which lacks information as to how durable the B- and T-cell immune response would last. However, it is worthy to note that UB-612 multitope subunit vaccine is the first designer vaccine to elicit a potent balanced B- and T-cell immunity against SARS-CoV-2 infection. Development of a new generation of such B-T combined vaccines has been explored. Large scale efficacy trials in geographically diverse areas enrolling young and elderly with various comorbidities, in both homologous and heterologous booster studies, are undergoing to accelerate the vaccine development for its timely introduction to prevent and control COVID.